In discounted cash flow (DCF) valuation techniques the value of the stock is estimated based upon present value of some measure of cash flow. Free cash flow to the firm (FCFF) is generally described as cash flows after direct costs and before any payments to capital suppliers.
Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Intrinsic Stock Value (Valuation Summary)
Year | Value | FCFFt or Terminal value (TVt) | Calculation | Present value at |
---|---|---|---|---|
01 | FCFF0 | |||
1 | FCFF1 | = × (1 + ) | ||
2 | FCFF2 | = × (1 + ) | ||
3 | FCFF3 | = × (1 + ) | ||
4 | FCFF4 | = × (1 + ) | ||
5 | FCFF5 | = × (1 + ) | ||
5 | Terminal value (TV5) | = × (1 + ) ÷ ( – ) | ||
Intrinsic value of Biogen Inc. capital | ||||
Less: Notes payable, including current portion (fair value) | ||||
Intrinsic value of Biogen Inc. common stock | ||||
Intrinsic value of Biogen Inc. common stock (per share) | ||||
Current share price |
Based on: 10-K (reporting date: 2021-12-31).
Disclaimer!
Valuation is based on standard assumptions. There may exist specific factors relevant to stock value and omitted here. In such a case, the real stock value may differ significantly form the estimated. If you want to use the estimated intrinsic stock value in investment decision making process, do so at your own risk.
Weighted Average Cost of Capital (WACC)
Value1 | Weight | Required rate of return2 | Calculation | |
---|---|---|---|---|
Equity (fair value) | ||||
Notes payable, including current portion (fair value) | = × (1 – ) |
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in thousands
Equity (fair value) = No. shares of common stock outstanding × Current share price
= ×
=
Notes payable, including current portion (fair value). See details »
2 Required rate of return on equity is estimated by using CAPM. See details »
Required rate of return on debt. See details »
Required rate of return on debt is after tax.
Estimated (average) effective income tax rate
= ( + + + + ) ÷ 5
=
WACC =
FCFF Growth Rate (g)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
2021 Calculations
2 Interest expense, after tax = Interest expense × (1 – EITR)
= × (1 – )
=
3 EBIT(1 – EITR)
= Net income attributable to Biogen Inc. + Interest expense, after tax
= +
=
4 RR = [EBIT(1 – EITR) – Interest expense (after tax) and dividends] ÷ EBIT(1 – EITR)
= [ – ] ÷
=
5 ROIC = 100 × EBIT(1 – EITR) ÷ Total capital
= 100 × ÷
=
6 g = RR × ROIC
= ×
=
FCFF growth rate (g) implied by single-stage model
g = 100 × (Total capital, fair value0 × WACC – FCFF0) ÷ (Total capital, fair value0 + FCFF0)
= 100 × ( × – ) ÷ ( + )
=
where:
Total capital, fair value0 = current fair value of Biogen Inc. debt and equity (US$ in thousands)
FCFF0 = the last year Biogen Inc. free cash flow to the firm (US$ in thousands)
WACC = weighted average cost of Biogen Inc. capital
Year | Value | gt |
---|---|---|
1 | g1 | |
2 | g2 | |
3 | g3 | |
4 | g4 | |
5 and thereafter | g5 |
where:
g1 is implied by PRAT model
g5 is implied by single-stage model
g2, g3 and g4 are calculated using linear interpoltion between g1 and g5
Calculations
g2 = g1 + (g5 – g1) × (2 – 1) ÷ (5 – 1)
= + ( – ) × (2 – 1) ÷ (5 – 1)
=
g3 = g1 + (g5 – g1) × (3 – 1) ÷ (5 – 1)
= + ( – ) × (3 – 1) ÷ (5 – 1)
=
g4 = g1 + (g5 – g1) × (4 – 1) ÷ (5 – 1)
= + ( – ) × (4 – 1) ÷ (5 – 1)
=